Adicet Bio, Inc. develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Company news centers on its off-the-shelf cell-therapy pipeline, including prulacabtagene leucel, or prula-cel, a CD20-targeted CAR gamma delta T cell therapy, and ADI-212, a PSMA-targeted candidate.
Recurring updates also cover clinical and regulatory disclosures, operating and financial results, biotechnology conference participation, inducement equity grants under Nasdaq rules, shareholder voting matters, Nasdaq listing compliance, and capital-structure actions involving common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.